Amedisys Inc

Amedisys — Q2 2016 Earnings Presentation

20 slides from Amedisys's earnings presentation, Aug 2, 2016

  1. Slide 1: Amedisys 2Q16 Earnings Call Supplemental Materials

    Amedisys 2Q16 Earnings Call Supplemental Materials August 2016 Exhibit 99.2

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and u

  3. Slide 3: Highlights and Summary Financial Results (Adjusted) – 2Q 2016

    Highlights and Summary Financial Results (Adjusted) – 2Q 2016 (1) Amedisys Consolidated Revenue Growth: +15% EBITDA: $30M EBITDA Margin: 8.3% EPS: $0.42 Amedisys Highlights Same Store Admissions: Medicare FFS: +4.1% Total Episodic: +5.3% Non-episodic: (2.2%) Other Statistics: Medicare recert rate: 3

  4. Slide 4: Home Health and Hospice Segment (Adjusted) – 2Q 2016

    Home Health and Hospice Segment (Adjusted) – 2Q 2016 (1) Organic growth continuing in episodic admissions (+5%); revenue mix improving (76% Medicare FFS) Non-Medicare per visit admissions declined 2% during 2Q16 compared to prior year CPV increase driven by planned wage increases (1%) and increased

  5. Slide 5: General & Administrative Expenses – Adjusted

    General & Administrative Expenses – Adjusted (1,2) Highlights Year over year adjusted total G&A increase of only 40 bps as a percent of revenue despite inclusion of $9M related to acquisitions in 2Q’16 Corporate G&A leverage beginning to materialize, down 50 bps as % of revenue sequentially The fina

  6. Slide 6: Amedisys Strategy: Four Areas of Focus

    Amedisys Strategy: Four Areas of Focus Updated 2Q 2016 Clinicians Patient Health Clinicians Patient Health Clinical Distinction Employer of Choice Operational Excellence and Efficiency Driving Growth Outstanding Outcomes for Our Patients In Their Homes Amedisys Care Centers & Clinical Teams Current:

  7. Slide 7: Amedisys 2Q16 Report Card

    Amedisys 2Q16 Report Card Category Grade Comments Growth Same store growth in home health (5.3% episodic admissions, 4.1% Medicare FFS), hospice (18% admissions) and personal care (14% billable hour growth) Quality Good progress on STARS with October preview score of 3.74 October preview vs. 3.50 in

  8. Slide 8: Driving Top Line Growth: Positive Metrics Across Business Segments

    Driving Top Line Growth: Positive Metrics Across Business Segments 234 Opportunities Prospected 45 Opportunities Under Review 13 Active Processes * Includes 3,792 (Q1) and 3,958 (Q2) completed episodes from Infinity acquisition 9% Growth 16% Growth Personal Care Total Hours / Quarter 38% Growth * In

  9. Slide 9: Operational Excellence: HCHB Implementation Timeline

    Operational Excellence: HCHB Implementation Timeline We have accelerated our HCHB implementation timeline with a target completion date of November 1, 2016, seven months ahead of our original plan. We are currently at 313 installs Care Centers 313 HCHB installs Note: Since rollout started, 1 Hospice

  10. Slide 10: Operational Excellence: Roadmap to EBITDA Improvement

    Operational Excellence: Roadmap to EBITDA Improvement HCHB disruption cost deeper than originally estimated but still contained to 2016 Disruption ($M) Incremental disruption driven by: recert rate impact, increased: OT pay, wireless, mileage, and other back office costs Revised Disruption: ~$18,000

  11. Slide 11: Operational Excellence: Roadmap to EBITDA Improvement

    Operational Excellence: Roadmap to EBITDA Improvement Deeper one time implementation costs, higher potential upside >$46M in annualized savings identified Rollout progressing well; increased visibility into efficiency initiatives + Incremental initiatives driving increased savings opportunities + *R

  12. Slide 12: Cost per Visit Components and Mitigation Plan

    Components 2Q’15 2Q’16 Variance Detail Mitigation Plan Salaries $59.08 $60.28 $1.20 $0.60 planned wage increases (1%) $0.30 HCHB disruption due to Admin/OT $0.30 clinician mix Expect normal levels post HCHB. 1.5% increase effective 7/1/16 Expect normal levels post HCHB Initiative focused on optimizi

  13. Slide 13: Becoming Employer of Choice: Improving Return on Human Capital

    Becoming Employer of Choice: Improving Return on Human Capital Total voluntary turnover continues to decline, closing in on goal of 22% by end of 2016 Implementation of HCHB allowing for increase in productivity targets Piloting proprietary resource allocation and productivity tool to maximize visit

  14. Slide 14: Clinical Distinction: Improvements in Stars

    Clinical Distinction: Improvements in Stars Metric Apr 16 Release Jul 16 Release Oct 16 Preview Quality of Patient Care Average 3.50 3.59 3.74 Entities at 4+ Stars 32% 36% 50% Quality of Patient Care Value Based Purchasing *Provider number data Year + / - Quality % $’s at risk or reward (based on 20

  15. Slide 15: CMS Update: Home Health and Hospice Reimbursement

    CMS Update: Home Health and Hospice Reimbursement Home Health Medicare Reimbursement FY16 FY17 Proposed FY18 Est. (Internal) Market basket update 2.3% 2.8% 1.0% Productivity adjustment (0.4%) (0.5%) -- Rebasing (2.4%) (2.3%) -- Nominal case-mix adjustment (1.0%) (1.0%) (1.0) Net impact – Industry (1

  16. Slide 16: Amedisys – Almost Family Combination Update

    Amedisys – Almost Family Combination Update---Almost Family Company Overview Map of all 67 CJR MSA’s Amedisys overlaps with 35 CJR MSA’s ’19-’20 2018 2017 2016 Amedisys & CJR Bundle price based on hospital specific and regional episode data Hospital downside risk starts Bundle pricing 1/3 hospital s

  17. Slide 17: Pre-Claim Review – Current and Proposed Process & Resources

    Pre-Claim Review – Current and Proposed Process & Resources The PCR process will drive more administrative complexities for HHAs and their referral sources, increasing costs and driving away referrals to less administratively complex providers who are more costly. Referral Intake Schedule Visit Elig

  18. Slide 18: Debt and Liquidity Metrics

    Debt and Liquidity Metrics Net debt defined as total debt outstanding on credit facility ($98M) less cash balance ($10M). Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($108M). Liquidity defined as the sum of cash balance and available revolving line of cr

  19. Slide 19: Adjusted EBITDA to Free Cash Flow Reconciliation

    Adjusted EBITDA to Free Cash Flow Reconciliation (1,2) The financial results for the three-month periods ended June 30, 2015, September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation

  20. Slide 20: Income Statement Adjustments

    Income Statement Adjustments (1) The financial results for the three-month periods ended June 30, 2015, September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP fin

Amedisys — Q2 2016 Earnings Presentation on 6ix